Member Info for dan1nat1

"too much H2, Q2, FY jargon"

Is that not just a typical FD, they know the numbers that's what they are there for ;)

Very true gammy...but we should really have smashed £1 today ;)

The sudden spike will let us know when "this is it" ;)

Don't get me wrong, I do not mean immediately as I posted I would guess Feb / Mar next year, by which time I expect we will be testing £2.50 + as a minimum after today's news.

Today is a great day, I'm not going to argue with you. We had 12 months money around 6 months ago...you do the sums.

And Mariushi wont be paying another 2.5m euros for something that doesn't meet the original target.

The time to do it will be Feb / Mar imo, we will have more meat on the bones of today's RNS and have every chance of being in the £'s rather than p's by then.

While we are on other stocks Farn is looking good to get back to £1+ before Friday.

A raise when we know something is working and has a clear to market plan, is a totally different prospect to a raise required for testing a theory. So a placing will not be the negative factor it could have been even just yesterday.

He is a she, and funds will be required within the next 6 months by which point I expect we will be a lot higher than we are now so that is not a deramp simple fact. Assuming we don't get taken out by then...

I think you are posting on the wrong board.

Pushing the bid...that’s a new one!

https://www.faron.com/investors/aim-rule-26

I think we all know what the mm’s see and what they show are very different things...

1/3 of patients is still a big number, and if as this RNS reads it is now proven to work then surely that is better than a possible drug at some point in the future, that may or may not work and may or may not work on a greater percentage of people?

Clearly you do not understand the market here.

Poor attempts at a cheaper entry point!

You are correct, but before the p3 trial this was fast tracked to go to market very quickly obviously that didn’t go to plan, but this part of the RNS makes me think there could be a chance of a quicker release than we had been thinking -
“seek advice on the future clinical development of Traumakine in the EU and the US for this precision treatment”

"However this greatly reduces it's potential market"

But massively increases its potential market had it been a total fail...

Shall we do all your research Wilfred?

Watch the latest interview, link posted plenty of times. He specifically says they have spoken to potential partners.

I suppose that depends on what you are willing to pay ;)

Only 31m shares in issue with a very small free float...nobody is going to want to get out of this anytime soon after that RNS!